title: Anaphylactic reactions during immunotherapy.
abstract: Subcutaneous immunotherapy (IT) with aeroallergen extracts is venerable treatment modality. The major risk associated with IT with commercial aeroallergen extracts is the uncommon occurrence of severe near-fatal or fatal anaphylaxis after injections. The objectives of this article are to review the reported incidences of severe anaphylaxis (near-fatal reactions and fatal reactions), define factors contributing to these events, and identify preventive measures that are likely to reduce or eliminate future fatal and near-fatal anaphylactic events. As with any treatment, anticipated benefits attributed to IT must be weighed against its potential risks.
authors.affiliation: Division of Allergy/Immunology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0563, USA.
authors.forename: Maziar
authors.initials: M
authors.lastname: Rezvani
authors.forename: David I
authors.initials: DI
authors.lastname: Bernstein
mesh_terms: D000485:Allergens / Q000009:adverse effects / Q000627:therapeutic use; D000707:Anaphylaxis / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control*; D003888:Desensitization, Immunologic / Q000009:adverse effects*; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy; D015994:Incidence; D007279:Injections, Subcutaneous; D012307:Risk Factors
chemical_list: D000485:Allergens